Author

Z. Itkin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4 Microbiology· 3 Cancer Biology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 10 Approach:experimental assay· 10 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:database / resource· 1 Approach:deep learning· 1

Frequent Co-Authors

A. Simeonov· 7 shared C. Klumpp-Thomas· 7 shared M. Shen· 6 shared P. Shinn· 6 shared W. Zheng· 6 shared C. Z. Chen· 5 shared H. Guo· 5 shared K. M. Wilson· 5 shared

Activity by Year

2020-2023 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersBiochemistry

A. Simeonov

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

High-throughput Approaches to Uncover Synergistic Drug Combinations in Leukemia

E. J. Chory, M. Wang, M. Ceribelli, A. M. Michalowska, S. Golas, E. Beck, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, S. Divakaran, J. Bradner, J. Khan, B. E. Gryder, C. J. Thomas, B. Z. Stanton

This paper identifies synergistic drug combinations in AML using high-throughput methods and open-source tools, revealing synergies affecting histone H3 lysine-27 modification.

SLAS Discovery · Jun 1, 2023Peer-reviewedCancer Biology

Application of Temperature-Responsive HIS-Tag Fluorophores to Differential Scanning Fluorimetry Screening of Small Molecule Libraries

M. H. Ronzetti, B. Baljinnyam, Z. Itkin, S. Jain, G. Rai, A. V. Zakharov, U. Pal, A. Simeonov

The paper develops a high-throughput differential scanning fluorimetry assay using HIS-tag fluorophores to screen small molecule libraries for protein interactions.

bioRxiv · Aug 31, 2022Biochemistry

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

J. H. Shrimp, J. Janiszewski, C. Z. Chen, M. Xu, K. M. Wilson, S. C. Kales, P. E. Sanderson, P. Shinn, Z. Itkin, H. Guo, M. Shen, C. Klumpp-Thomas, S. G. Michael, W. Zheng, A. Simeonov, M. D. Hall

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

bioRxiv · Feb 4, 2022Biochemistry

mTOR Inhibition Overcomes RSK3-mediated Resistance to BET Inhibitors in Small Cell Lung Cancer

A. Kumari, L. Gesumaria, Y.-J. Liu, V. K. Hughitt, X. Zhang, M. Ceribelli, K. M. Wilson, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, C. Thomas, B. A. Mock, D. S. Schrump, H. Chen

This study identifies mTOR inhibition as a strategy to overcome RSK3-mediated resistance to BET inhibitors in small cell lung cancer, enhancing apoptosis and antitumor efficacy.

bioRxiv · Nov 8, 2021Cancer Biology

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry

M. Xu, M. Pradhan, K. Gorshkov, J. D. Petersen, M. Shen, H. Guo, W. Zhu, C. Klumpp-Thomas, S. Michael, M. Itkin, Z. Itkin, M. R. Straus, J. Zimmerberg, W. Zheng, G. Whittaker, C. Z. Chen

This paper develops a high throughput screening assay using SARS-CoV-2 pseudotyped particles to identify inhibitors of viral entry, finding 7 active compounds effective against both pseudotyped particles and live virus.

bioRxiv · Oct 4, 2021Pharmacology & Toxicology

Modulation of triple artemisinin-based combination therapy pharmacodynamics by Plasmodium falciparum genotype

M. R. Ansbro, Z. Itkin, L. Chen, G. Zahoranszky-Kohalmi, C. Amaratunga, O. Miotto, T. Peryea, C. V. Hobbs, S. Suon, J. M. S, A. M. Dondorp, R. W. van der Pluijm, T. Wellems, A. Simeonov, R. T. Eastman

The paper evaluates drug-drug interactions in triple artemisinin-based combination therapies (TACTs) using an in vitro high-throughput process to identify genotype-dependent susceptibility and antagonism.

ACS Pharmacology & Translational Science · Dec 11, 2020Peer-reviewedMicrobiology

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

C. Z. Chen, P. Shinn, Z. Itkin, R. Eastman, R. Bostwick, L. Rasmussen, R. Huang, M. Shen, X. Hu, K. M. Wilson, B. Brooks, H. Guo, T. Zhao, C. Klumpp-Thomas, A. Simeonov, , W. Zheng

The paper identifies 319 compounds with anti-SARS-CoV-2 activities through a high-throughput screen, including 91 approved drugs and 49 investigational drugs, with 230 compounds previously unreported.

bioRxiv · Aug 18, 2020Microbiology

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro

T. Bobrowski, L. Chen, R. T. Eastman, Z. Itkin, P. Shinn, C. Chen, H. Guo, W. Zheng, S. Michael, A. Simeonov, M. Hall, A. V. Zakharov, E. N. Muratov

This study identifies synergistic and antagonistic drug combinations against SARS-CoV-2 in vitro using in silico prioritization and experimental testing.

bioRxiv · Jun 29, 2020Microbiology

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay

Q. M. Hanson, K. M. Wilson, M. Shen, Z. Itkin, R. T. Eastman, P. Shinn, M. D. Hall

The paper develops an AlphaLISA assay to measure SARS-CoV-2 spike RBD-ACE2 binding and identifies 25 drug candidates that disrupt this interaction.

bioRxiv · Jun 16, 2020Biochemistry

Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research

K. R. Brimacombe, P. C. Scully, T. Zhao, R. T. Eastman, X. Hu, K. Wang, M. Backus, B. Baljinnyam, C. Z. Chen, L. Chen, Y. Cheng, D. P. Davis, K. Duerr, T. Eicher, A. Friedman, , M. D. Hall

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

bioRxiv · Jun 4, 2020 · PreprintBiochemistry

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators

K. Gorshkov, C. Z. Chen, R. Bostwick, L. Rasmussen, M. Xu, M. Pradhan, B. N. Tran, W. Zhu, K. Shamim, W. Huang, X. Hu, M. Shen, C. Klumpp-Thomas, Z. Itkin, P. Shinn, , W. Zheng

The paper identifies six autophagy modulators that block SARS-CoV-2 cytopathic effects in Vero-E6 cells with EC50 values between 2.0 and 13 µM.

bioRxiv · May 16, 2020Pharmacology & Toxicology